Reviewed by Sarim Mir, MD — Board-Certified Neurologist, Mir Neurology (Hagerstown & Cumberland, MD)
Key takeaways
- Tavapadon is an investigational, once-daily oral medicine for Parkinson’s disease that is not yet FDA-approved.
- It works in a new way — as a D1/D5-selective dopamine partial agonist — which is different from most current dopamine agonists.
- AbbVie submitted its application to the FDA in late 2025, with a decision expected around the first half of 2026.
- The goal is to improve motor control while potentially reducing some side effects, though it must complete FDA review first.
- Talk with a neurologist before changing any Parkinson’s treatment plan.
What changed
In September 2025, AbbVie submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, an investigational once-daily pill for Parkinson’s disease. Industry watchers expect an FDA decision in the first half of 2026. Tavapadon was studied in the large Phase 3 TEMPO trial program, which looked at its use both on its own (monotherapy) in early Parkinson’s and alongside levodopa in people with more advanced symptoms. It is important to be clear: tavapadon is investigational and has not yet been approved. Until the FDA completes its review, it is not available as a prescription treatment.
Plain-English explainer of the condition
Parkinson’s disease is a long-term brain condition that affects movement. Deep in the brain, certain cells make a chemical messenger called dopamine, which helps your body move smoothly. In Parkinson’s, these dopamine-making cells gradually slow down and are lost. As dopamine drops, people may notice a tremor (shaking), stiffness, slowness of movement, and balance problems. Symptoms usually start mild and change slowly over years. Many people also notice non-movement symptoms such as trouble sleeping, constipation, or changes in mood.
There is no cure for Parkinson’s today, but there are effective treatments that help control symptoms and support daily life. The most common medicine, levodopa, gives the brain more raw material to make dopamine. Other medicines, called dopamine agonists, act like dopamine by switching on dopamine receptors — tiny “docking stations” on brain cells. Over time, the right combination of medicines, exercise, and regular neurology care can help many people stay active and independent.
How it works / what’s different
Dopamine doesn’t act on just one type of receptor. There are several kinds, often grouped into “D1-like” (D1 and D5) and “D2-like” (D2, D3, and D4). Most dopamine agonists used for Parkinson’s today mainly target the D2 and D3 receptors. Tavapadon is different because it selectively targets the D1 and D5 receptors instead.
Tavapadon is also a partial agonist. That means it turns these receptors on only part of the way, rather than fully. The theory is that this gentler, more selective stimulation might improve movement while causing fewer of the side effects sometimes linked to broader dopamine medicines. In the Phase 3 TEMPO studies, tavapadon improved motor scores when used alone in early Parkinson’s, and increased “good ON time” (time with well-controlled movement and without troublesome involuntary movements) when added to levodopa. It is taken once a day by mouth.
Because tavapadon is still under FDA review, its full safety profile, approved uses, and place among existing therapies will become clearer only if and when it is approved. No medicine — including tavapadon — slows, stops, or cures Parkinson’s; these treatments are designed to help manage symptoms.
What this means for you in Hagerstown & Cumberland
If you or a loved one is living with Parkinson’s in Western Maryland, news about a new pill can bring real hope — and a lot of questions. At Mir Neurology, Dr. Sarim Mir and our team follow developments like tavapadon closely so we can give you grounded, up-to-date guidance instead of hype. Whether or not tavapadon is approved, the foundation of good Parkinson’s care stays the same: an accurate diagnosis, a treatment plan tailored to you, regular check-ins, and adjustments as your needs change.
Learn more about our Parkinson’s disease care and movement disorders services.
We serve patients across Hagerstown, Cumberland, and the surrounding communities, and we’re happy to review your current regimen, discuss whether emerging options may fit your situation in the future, and answer your questions in plain language. Call (301) 797-7600 to request an appointment or request an appointment online.
Frequently asked questions
Is tavapadon available now? No. As of mid-2026, tavapadon is investigational and under FDA review. A decision is expected around the first half of 2026, but it cannot be prescribed unless and until the FDA approves it.
How is tavapadon different from other Parkinson’s medicines? It is a once-daily pill that selectively targets the D1 and D5 dopamine receptors as a partial agonist. Most current dopamine agonists mainly target D2 and D3 receptors, so tavapadon takes a different approach that researchers hope may improve motor control with a different side-effect profile.
Will tavapadon cure Parkinson’s? No. Tavapadon is being studied to help manage Parkinson’s symptoms, not to cure or stop the disease. No current Parkinson’s medicine cures the condition.
This article is for general education and is not a substitute for personalized medical advice; please consult a qualified clinician about your specific situation.
Sources: NeurologyLive — Previewing Expected FDA Decisions in Neurology for 2026, Being Patient — Dementia Drug Trials and Regulatory Decisions to Watch in 2026
Need to talk to a neurologist about this?
Mir Neurology offers same-week appointments in Hagerstown & Cumberland, MD. No referral needed for most plans.
